Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
Undervalued with solid track record.
Share Price & News
How has Boston Scientific's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BSX's share price has been volatile over the past 3 months.
7 Day Return
DE Medical Equipment
1 Year Return
DE Medical Equipment
Return vs Industry: BSX underperformed the German Medical Equipment industry which returned 9.4% over the past year.
Return vs Market: BSX exceeded the German Market which returned -14.3% over the past year.
Price Volatility Vs. Market
How volatile is Boston Scientific's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Boston Scientific undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BSX (€32.4) is trading below our estimate of fair value (€49.71)
Significantly Below Fair Value: BSX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BSX is good value based on its PE Ratio (10.4x) compared to the Medical Equipment industry average (48.6x).
PE vs Market: BSX is good value based on its PE Ratio (10.4x) compared to the German market (17.1x).
Price to Earnings Growth Ratio
PEG Ratio: BSX's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: BSX is good value based on its PB Ratio (3.5x) compared to the DE Medical Equipment industry average (4.8x).
How is Boston Scientific forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BSX's earnings are forecast to decline over the next 3 years (-42.7% per year).
Earnings vs Market: BSX's earnings are forecast to decline over the next 3 years (-42.7% per year).
High Growth Earnings: BSX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BSX's revenue (7.7% per year) is forecast to grow faster than the German market (3.9% per year).
High Growth Revenue: BSX's revenue (7.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BSX's Return on Equity is forecast to be high in 3 years time (24.3%)
How has Boston Scientific performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BSX has a large one-off loss of $642.0M impacting its December 31 2019 financial results.
Growing Profit Margin: BSX's current net profit margins (43.8%) are higher than last year (17%).
Past Earnings Growth Analysis
Earnings Trend: BSX has become profitable over the past 5 years, growing earnings by 72.2% per year.
Accelerating Growth: BSX's earnings growth over the past year (181.3%) exceeds its 5-year average (72.2% per year).
Earnings vs Industry: BSX earnings growth over the past year (181.3%) exceeded the Medical Equipment industry 17%.
Return on Equity
High ROE: BSX's Return on Equity (33.9%) is considered high.
How is Boston Scientific's financial position?
Financial Position Analysis
Short Term Liabilities: BSX's short term assets ($4.7B) do not cover its short term liabilities ($4.9B).
Long Term Liabilities: BSX's short term assets ($4.7B) do not cover its long term liabilities ($11.8B).
Debt to Equity History and Analysis
Debt Level: BSX's debt to equity ratio (72.1%) is considered high.
Reducing Debt: BSX's debt to equity ratio has increased from 65.7% to 72.1% over the past 5 years.
Debt Coverage: BSX's debt is not well covered by operating cash flow (18.4%).
Interest Coverage: BSX's interest payments on its debt are well covered by EBIT (4.1x coverage).
What is Boston Scientific's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BSX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate BSX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BSX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BSX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BSX's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike Mahoney (54yo)
Mr. Michael F. Mahoney, also known as Mike, has been Chairman of Boston Scientific Corporation since May 3, 2016, its Chief Executive Officer since November 1, 2012 and has been its President since October ...
CEO Compensation Analysis
Compensation vs Market: Mike's total compensation ($USD15.76M) is above average for companies of similar size in the German market ($USD5.19M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
|Executive VP & CFO||6.25yrs||US$4.03m||0.019% $8.5m|
|Executive VP of Operations||5.17yrs||US$3.20m||0.0047% $2.1m|
|Executive VP & President of Rhythm Management||10.17yrs||US$4.03m||0.021% $9.6m|
|Executive VP & President of Interventional Cardiology||7.25yrs||US$3.37m||0.0057% $2.6m|
|VP, Global Controller & Chief Accounting Officer||0.75yr||no data||0.0024% $1.1m|
|Senior VP & Chief Information Officer||4.33yrs||no data||0.0013% $565.0k|
|Vice President of Investor Relations||6.33yrs||no data||no data|
|Senior VP||2.42yrs||no data||0.00086% $388.7k|
|Vice President of Global Marketing & New Business Development of Peripheral Interventions||no data||no data||no data|
Experienced Management: BSX's management team is seasoned and experienced (6.3 years average tenure).
|Lead Independent Director||3.92yrs||US$340.11k||0.0026% $1.2m|
|Independent Director||4.75yrs||US$319.98k||0.0016% $705.1k|
|Independent Director||5yrs||US$299.98k||0.000070% $31.6k|
|Independent Director||6.25yrs||US$320.20k||0.0039% $1.8m|
|Independent Director||4yrs||US$299.98k||0.0019% $872.4k|
|Independent Director||3.75yrs||US$299.98k||no data|
|Independent Director||5yrs||US$324.98k||0.0049% $2.2m|
|Independent Director||10.33yrs||US$302.47k||0.0036% $1.6m|
|Independent Director||11yrs||US$319.98k||0.0022% $1.0m|
Experienced Board: BSX's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: BSX insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Boston Scientific Corporation's company bio, employee growth, exchange listings and data sources
- Name: Boston Scientific Corporation
- Ticker: BSX
- Exchange: DB
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$49.154b
- Listing Market Cap: US$45.202b
- Shares outstanding: 1.40b
- Website: https://www.bostonscientific.com
Number of Employees
- Boston Scientific Corporation
- 300 Boston Scientific Way
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BSX||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||May 1992|
|BSX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 1992|
|BSX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||May 1992|
|0HOY||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 1992|
|BSX||BRSE (Berne Stock Exchange)||Yes||Common Stock||CH||CHF||May 1992|
|BSX||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||May 1992|
|BSXC||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||May 1992|
|B1SX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH REPR 1 COM||BR||BRL||Dec 2019|
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions therapy products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as certain peripheral vessels; and structural heart therapies. It also provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy, acoustic pulse thrombolysis, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, radiofrequency and cryotherapy ablation systems, microcatheters, and drainage catheters to treat various cancers. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to treat abnormalities; remote patient management system; implantable cardiac resynchronization therapy pacemaker systems; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, mapping system, and other accessories. Further, it provides products to diagnose and treat diseases of the gastrointestinal and pulmonary conditions; products to treat various urological and pelvic conditions; deep brain stimulation systems for the treatment of parkinson's disease, tremor, and intractable primary and secondary dystonia; and spinal cord stimulator systems for the management of chronic pain. The company was founded in 1979 and is headquartered in Marlborough, Massachusetts.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/09 20:34|
|End of Day Share Price||2020/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.